Effect on Weight Loss of Exenatide Versus Placebo

NCT00375492 on ClinicalTrials.gov · last registry update 2015-04-07

A small phase 3 — 196 participants, against a typical 424. The sponsor logged completion for February 2008. Primary outcome, as filed: Change From Baseline in Body Weight. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 196
Started: 2006-09
Primary completion: 2008-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Body Weight

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.